Key result
Higher serum suPAR linked to ~2-fold higher odds of arterial stiffness in hemodialysis patients.
Why the study?
Cardiovascular diseases remain a significant cause of death in hemodialysis patients, prompting investigation into the role of soluble urokinase-type plasminogen activator receptor in arterial stiffness.
Does higher serum suPAR level correlate with increased arterial stiffness in chronic hemodialysis patients?
Cross-Sectional (n=135)
No
Does higher serum suPAR level correlate with increased arterial stiffness in chronic hemodialysis patients?
Odds Ratio: 2.05 (95% CI 1.48–2.7)
p-value: p=<0.001
Serum suPAR is a potential biomarker for arterial stiffness and increased cardiovascular risk in patients undergoing maintenance hemodialysis.
suPAR may aid risk stratification in hemodialysis; leaves open causal role and need for prospective validation.
Cardiovascular diseases (CVDs) remain a significant cause of death in hemodialysis (HD) patients. To explore their associations, we examine the role of soluble urokinase-type plasminogen activator receptor (suPAR) in arterial stiffness in chronic HD patients. From June to August 2020, we recruited 135 chronic HD patients. The arterial stiffness group included patients with a carotid–femoral pulse-wave velocity (cfPWV) of >10 m/s. Fifty-five HD patients (40.7%) were in the arterial stiffness group. They had a higher prevalence of diabetes (p = 0.001) and hypertension (p = 0.039), were older (p = 0.007) and had higher aortic systolic blood pressure (p = 0.034), brachial systolic blood pressure (p = 0.025), glucose (p = 0.019), C-reactive protein (p = 0.039), and AIx75 (p = 0.003) and suPAR (p < 0.001) levels than the control group. After we performed multivariable logistic regression analysis, except age and glucose, serum suPAR (odds ratio [OR]: 2.05; 95% confidence interval [CI]: 1.48–2.70, p < 0.001) was independently associated with arterial stiffness in chronic HD patients. In the multivariable linear regression analysis, suPAR positively correlated with cfPWV (β = 0.475, p < 0.001) and could serve as a biomarker for arterial stiffness development in patients undergoing HD.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2023) conducted a cross-sectional in Chronic Hemodialysis (n=135). Serum soluble urokinase-type plasminogen activator receptor (suPAR) level vs. Lower suPAR level was evaluated on Arterial stiffness (carotid-femoral pulse-wave velocity >10 m/s) (OR 2.05, 95% CI 1.48-2.70, p=<0.001). Serum suPAR was independently associated with arterial stiffness in chronic hemodialysis patients (OR 2.05, 95% CI 1.48-2.70, p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: